IRCT20190624043993N2.

Study name	Evaluation effects of the standard regimen along with ivermectin on treatment of corona virus type 2 pneumonia
Methods	Trial design: open‐label RCT with 2 parallel arms Type of record: trial register entry Sample size: 50 Setting: NR Country: Iran Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: IRCT20190624043993N2 Date of registration: 12 July 2020
Participants	Inclusion criteria Definite (clinical and positive PCR) COVID‐19 disease < 48 hours have passed since the onset of symptoms Exclusion criteria Underlying liver disease/hepatitis Underlying haematological disorders Seizures and encephalopathy Known allergies to ivermectin Pregnancy/lactation People who themselves or their legal guardians are reluctant to participate or continue clinical trials
Interventions	Details of intervention Type and dose: ivermectin 0.15 mg/kg, once daily, unclear duration of intervention Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care according to national guideline administered in both study arms
Outcomes	Primary study outcome Clinical radiographic response at 7 and 14 days Relevant review outcomes planned Virological response (PCR) at 7 days Additional study outcomes None
Starting date	22 August 2020
Contact information	Foroud Shahbazi Kermanshah University of Medical Sciences Parastar Blve 1673‐67145 Kermanshah Iran Foroud08@gmail.com
Notes	Recruitment status: NR Prospective completion date: 19 February 2021 Date last update posted: 12 July 2020 Sponsor/funding: Kermanshah University of Medical Sciences